Pharmaceutical Compositions for Nasal Delivery

Abstract

The present invention provides a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically effective amount of an opioid antagonist and a pharmaceutically acceptable carrier.The composition is preferably in the form of a powder produced by spray drying, which is then loaded into a single-use nasal applicator.In this regard, preferred pharmaceutically acceptable carriers include disaccharides (e.g., lactose or trehalose) and dextrins (e.g., cyclodextrin or maltodextrin), preferably combined and spray-dried together.The composition may further comprise an alkyl sugar, preferably a sucrose ester such as sucrose monolaurate.The composition and applicator can be used to treat opioid overdose in a subject.

Description

[Technical Field]

[0001] The present invention relates to novel pharmaceutical compositions containing opioid antagonists useful, inter alia, in the treatment of opioid / opiate overdose. The present invention also relates to methods for making such compositions and formulating them into dosage forms, as well as their use in the treatment of opioid / opiate overdose. [Background technology]

[0002] The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or common general knowledge.

[0003] Drug addiction is a global problem, and opioid dependence is a major component of this problem. Opioids and opiates are highly addictive. People often begin using illegal opioids such as heroin (diamorphine) for recreational purposes, which usually leads to dependence.

[0004] That said, a new cohort of opioid addicts has begun to emerge over the past decade or so, particularly in the United States: so-called "white-collar" addicts who have become dependent on prescription opioids, typically initiated for the treatment of pain.

[0005] This is due to the increasingly widespread use of pharmaceutical opioids as analgesics in the treatment of moderate to severe chronic cancer pain, and acute pain (e.g., during recovery from surgery and breakthrough pain). In addition, their use is increasing in the management of chronic non-malignant pain.

[0006] People who become addicted to prescription opioids may move on to illegal ("street") drugs such as heroin, which may be because heroin is cheaper and (relatively) more readily available than prescription opioids.

[0007] In 2010, it was estimated that there were 15.5 million opioid-dependent individuals worldwide. Prevalence rates in Australasia, Western Europe, and North America were higher than the global pooled prevalence rate. According to a 2017 European Monitoring Centre for Drugs and Drug Addiction report, there were an estimated 1.3 million high-risk opioid users in Europe in 2016. The opioid crisis has particularly affected the United States, which has escalated in recent years.

[0008] Thus, opioid addiction is a significant health problem, with long-term opioid use associated with substantially increased risk of premature death from drug overdose, violence and suicide, and a variety of other well-known health problems, and its socioeconomic impact in terms of medical costs, lost productivity, addiction treatment, and criminal activity is growing (see Florence et al, Med. Care., 54, 901 (2016)).

[0009] Opioid addicts typically feed their addiction by directly purchasing opioids "off the street" in the form of opioid powders (e.g., heroin). Heroin is typically mixed (or "cut") with additives by drug dealers before being sold, the amounts and identities of which are often unknown to the abuser. Furthermore, addicts are increasingly being sold and abusing more potent opioids, such as fentanyl and its analogs, intended for the treatment of pain and other conditions (see, e.g., Prekupec et al., J. Addict. Med., 11, 256-265 (2017)).

[0010] Even without these additional issues, opioids are extremely dangerous drugs if not delivered under medical supervision. Because there is no quality control for illegal drugs sold, particularly with regard to the purity and strength issues mentioned above, the entire process is like a "lottery," which contributes to the risk and likelihood of overdose.

[0011] Opioid overdose leads to a slowing of the heart rate and breathing, leading to hypoxia. Hypoxia not only has short- and long-term effects on the central nervous system, including coma and permanent brain damage, but often leads to death. Opioid overdoses, particularly heroin, are extremely common. In 2015, drug overdoses accounted for 52,404 U.S. deaths, of which 33,091 (63.1%) involved opioids (see Rudd et al., MMWR, 65, 1445 (2016)). Overdoses in first-time heroin users are not unheard of.

[0012] Subjects who have overdosed on opioids require emergency medical treatment. The only drugs available to effectively treat opioid overdose are opioid receptor antagonists, which act by binding to opioid receptors and displacing opioid agonists (e.g., heroin) without eliciting their own opioid effects, whether intended (e.g., euphoria) or unintended and / or potentially dangerous (including respiratory depression). Emergency administration of opioid antagonists can reduce the severity of opioid addiction (sometimes completely), essentially "reversing" an opioid overdose.

[0013] Opioid antagonists are administered as an intravenous solution in hospital accident and emergency departments by medically qualified staff, although relatively few treatments are available for the treatment of opioid overdose (or suspected overdose) outside the hospital setting.

[0014] Two such commercially available treatments include an opioid antagonist, naloxone, delivered in a single dose either as a liquid nasal spray (Narcan®, sprayed directly into one nostril) or as an auto-injector (Evzio®, which delivers the drug by intramuscular or subcutaneous injection). These treatments are often used by first responders (i.e., non-medically qualified personnel such as ambulance crews, paramedics, police officers, family members, friends, or other caregivers) to buy time until more qualified medical assistance becomes available.

[0015] These products are undoubtedly effective as life-saving aids. Naloxone and other opioid antagonists are highly water-soluble drugs, so an effective dose of naloxone or other opioid antagonists can be dissolved in a small volume of liquid (100 μL) in a product like Narcan to treat an opioid overdose. This allows for rapid action in an emergency.

[0016] However, in about one-third of cases, Narcan is known to require more than one dose to result in overdose reversal. Furthermore, Narcan has the drawback that it must not be frozen (otherwise it cannot be dispensed). This is problematic in cold climates, for example, if the product is left in a first responder's car overnight.

[0017] On the other hand, Evzio is a parenteral product that requires a needle, which poses significant difficulties and / or problems for some first responders in emergency situations.

[0018] Due to the significant increase in overdose deaths due to opioid misuse, there is a considerable demand for opioid overdose prevention medications, and there is also a clear clinical need for alternative and / or improved agents in terms of strength, onset and duration of action, and reproducibility and reliability in emergency situations (which is undoubtedly the case when treating opioid overdose).

[0019] In addition to the commercially available product, Narcan, liquid nasal sprays are also disclosed in International Patent Application No. 2018 / 064672 and U.S. Patent Applications Nos. 2018 / 0092839A and 2019 / 0070105A.

[0020] Dry powder formulations comprising opioid antagonists that can be administered by inhalation or intranasal administration are known, inter alia, from International Patent Applications Nos. 2010 / 142696 and 2019 / 038756, and US Patent Application No. 2018 / 0092839A.

[0021] Russo et al. (J. Pharm. Sci., 95, 2253 (2006)) discloses spray-drying an opioid analgesic compound, namely morphine, with a number of excipients. Spray-dried formulations are also disclosed by Vengerovich et al., Bulletin of Experimental Biology and Medicine, 163, 737 (2017), which attempted to microencapsulate naloxone in various materials, including 2-hydroxypropyl-β-cyclodextrin, with the aim of developing a sustained-release formulation based on a polymeric carrier for emergency medical use.

[0022] Sugar esters are a class of natural and biodegradable nonionic surfactants consisting of a hydrophilic sugar "headgroup" esterified with a fatty acid. The properties of sugar esters vary depending on the nature of the sugar and fatty acid used and the degree of sugar esterification. They are made from natural products, sugars, and edible fats, and are tasteless, odorless, and biodegradable. They are relatively nontoxic, with an acceptable daily intake of up to 30 mg / kg (Joint FAO / WHO Expert Committee on Food Additives (JECFA)). Sugar esters, particularly sucrose esters, are widely used in the food and cosmetic industries but have so far been relatively underutilized in pharmaceutical formulations (see, for example, the review article by Szuts and Szabo-Revesz in Int. J. Pharm., 433, 1 (2012)).

[0023] Sucrose esters are known to be excellent oil-in-water emulsifiers. For example, emulsion-based compositions containing sucrose esters are described in International Patent Application No. 2005 / 065652. See also International Patent Application No. 2003 / 061632.

[0024] Sucrose esters have also been used to improve the bioavailability of poorly water-soluble drugs, such as cyclosporine, in orally administered dosage forms (see Hahn and Sucker, Pharm. Res., 6, 958 (1989)). (Note that naloxone and other opioid antagonists are highly water-soluble.)

[0025] Other oral dosage forms containing sucrose esters are described, inter alia, in International Patent Application No. 2016 / 016431.

[0026] International Patent Applications Nos. 2015 / 095389 and 2018 / 089709, and U.S. Patent No. 9,895,444 also disclose that related compounds, sugar ethers, and in particular alkyl glycosides, can enhance the bioavailability of opioid compounds in liquid nasal sprays. Sucrose esters are also mentioned in these documents. A similar drug delivery vehicle is disclosed in U.S. Patent Application No. 2016 / 0045474. Furthermore, Kurti et al. investigated the effects of sucrose esters on epithelial permeability in a culture model (see Toxicology in Vitro, 26, 445 (2012)), and Li et al. investigated the effects of various surfactants, including sucrose laurate, in an in vivo absorption study in rats using sumatriptan as a model drug substance (see Drug Delivery, 23, 2272 (2016)).

[0027] However, to Applicant's knowledge, the use of sucrose esters in solid (eg, powder) formulations intended for intranasal delivery has not been reported.

[0028] We have now unexpectedly found that it is possible to formulate opioid antagonists in the form of dry powder compositions that provide surprisingly substantial improvements in the bioavailability of the opioid antagonist and, even more surprisingly, an increased rate of absorption of the opioid antagonist compared to commercially available products. In particular, we have found that compositions produced by a spray-drying process using certain combinations of carrier materials disclosed below, and / or similar dry powder compositions that include alkyl sugars such as sucrose esters, can produce these unexpected effects. Summary of the Invention

[0029] According to a first aspect of the present invention, there is provided a solid pharmaceutical formulation / composition suitable for nasal delivery of an opioid antagonist, comprising a pharmacologically effective amount of an opioid antagonist and a pharmaceutically acceptable carrier material.

[0030] According to a second aspect of the present invention, there is provided a solid pharmaceutical formulation / composition in the form of a powder suitable for nasal delivery of an opioid antagonist, comprising a pharmacologically effective amount of an opioid antagonist, optionally an alkyl sugar, and a pharmaceutically acceptable carrier material.

[0031] Preferably, the powder is produced by a process of spray drying. According to a third aspect of the present invention, there is provided a solid pharmaceutical formulation / composition in the form of a spray-dried powder suitable for nasal delivery of an opioid antagonist, comprising a pharmacologically effective amount of an opioid antagonist and pharmaceutically acceptable carrier materials, more preferably at least two pharmaceutically acceptable carrier materials, at least one of the carrier materials being a disaccharide and at least one of the carrier materials being a dextrin.

[0032] The compositions of the first, second and third aspects of the present invention are hereinafter collectively referred to as "the compositions of the present invention."

[0033] It will be well understood by those skilled in the art that the term "solid" includes any form of matter that retains its shape and density when unconfined and / or whose molecules are generally as tightly packed as the repulsive forces between them allow.

[0034] Opioid antagonists that can be used in the compositions of the present invention include any compound that has little or no opioid activity but is capable of displacing an opioid agonist from an opioid receptor, thereby reversing or preventing the pharmacological effects of the opioid agonist, whether such effects are intended (euphoria, sedation and / or reduced craving) or unintended (loss of consciousness, decreased heart rate, decreased pulmonary function, hypoxia, etc.). In this regard, the term "opioid agonist" includes exogenous opioid receptor ligands (i.e., those described above) and endogenous opioid receptor ligands (e.g., endorphins).

[0035] Thus, the opioid antagonist includes naloxone, nalmefene, and naltrexone, or their pharmacologically acceptable salts. Preferred salts of these compounds include hydrochloride salts. Naloxone and nalmefene (and any salts) are particularly preferred.

[0036] In the context of the present invention, the term "opioid antagonist" may also include active pharmaceutical ingredients known to be partial antagonists of opioid receptors, such as buprenorphine. Buprenorphine is a partial agonist at the μ-opioid receptor, and therefore can be referred to as a "partial antagonist of the opioid receptor." Buprenorphine has a high binding affinity and competes with other agonists, such as methadone, heroin, and morphine, at the μ-opioid receptor. The opioid agonist effect of buprenorphine is less than the maximum effect of other "full" opioid agonists, such as morphine, and is limited by a "ceiling" effect. Therefore, this drug produces less physical dependence than other opioid agonists, such as heroin, morphine, or methadone, and is therefore used as a substitution therapy. In opioid-tolerant subjects, the risk of overdose is reduced, and recreational value is reduced. Buprenorphine is included in the WHO Essential Medicines List for the treatment of opioid dependence. By displacing full agonists, buprenorphine may be useful in the context of the present invention because it can reverse opioid overdose while inducing less withdrawal symptoms compared to full antagonists.

[0037] The amount of opioid antagonist used in the compositions of the present invention should be sufficient to antagonize the effects of the opioid receptor agonist (exogenous and / or endogenous), induce withdrawal symptoms, and / or reverse the above-mentioned pharmacological effects. The pharmacologically appropriate amount of opioid antagonist (or its salt) can be determined by those skilled in the art and may vary depending on the type and severity of the condition being treated and what is most appropriate for each individual patient. It will also likely vary depending on the nature of the formulation and route of administration, the type and severity of the condition being treated, and the age, weight, sex, renal function, hepatic function, and response of the particular patient being treated.

[0038] The total amount of opioid antagonist that can be used in the compositions of the present invention depends on the nature of the active compound contained, but can range from about 0.1%, such as about 1%, for example, about 2%, to a maximum of about 95%. For example, the amount of opioid antagonist can be from about 5% by weight (e.g., about 20% by weight), such as about 10% by weight, to about 95% by weight, such as about 75% by weight, for example, about 50% by weight, for example, about 40% by weight, based on the total weight of the composition.

[0039] Suitable dosages of opioid antagonist per unit dose (calculated as the free acid / base) range from about 1 mg to about 60 mg (e.g., about 40 mg), such as about 2 mg to about 30 mg (e.g., about 20 mg, such as about 10 mg), depending on the opioid antagonist used.

[0040] Suitable dosages of naloxone (calculated as the free base) may range from about 1 mg to about 20 mg (e.g., about 15 mg), such as from about 1.5 mg to about 10 mg, and thus may be about 1.8 mg, about 5.4 mg, about 9.0 mg (e.g., about 10.8 mg), more preferably about 3.6 mg, and especially about 7.2 mg.

[0041] A suitable dosage of nalmefene (calculated as the free base) per unit dose may be from about 0.5 to about 10 mg, more preferably from about 1 mg to about 6 mg, including about 1.5 mg, especially about 3.0 mg.

[0042] A suitable dosage of naltrexone (calculated as the free base) per unit dosage may be from about 1 mg to about 20 mg (eg, about 15 mg), more preferably from about 1.5 mg to about 10 mg.

[0043] In relation to any of the foregoing aspects of the invention, suitable pharmaceutically acceptable carrier materials that can be used in the composition include any relevant material that, in the solid state, under normal storage conditions, is suitable for (and / or approved for) pharmaceutical use and / or intranasal delivery, is able to maintain its physical and / or chemical integrity, and / or does not affect the physical and / or chemical integrity of the opioid antagonist and / or other components that may be present in the composition (such as alkyl sugars).

[0044] The phrase "maintaining physical and chemical integrity" essentially means chemical stability and solid state stability.

[0045] "Chemical stability" includes that any composition of the present invention, in isolated solid form or when loaded into a nasal applicator or reservoir therefor (with or without appropriate pharmaceutical packaging), can be stored under normal storage conditions with insignificant chemical deterioration or decomposition.

[0046] "Solid state stable" includes that any composition of the invention, in isolated solid form or when loaded into a nasal applicator or reservoir therefor (with or without appropriate pharmaceutical packaging), can be stored under normal storage conditions with insignificant degree of chemical degradation or solid state transformation (e.g., crystallization, recrystallization, loss of crystallinity, solid state phase transition (e.g., between glassy and rubbery, or to an aggregate form), hydration, dehydration, solvation, or desolvation).

[0047] Examples of "normal storage conditions" for compositions of the invention, whether loaded into an applicator, device, drug reservoir (such as a canister or container), include temperatures of about -50°C to about +80°C (preferably about -25°C to about +75°C, such as about 50°C) for extended periods of time (i.e., about 12 months or more, such as about 6 months), and / or pressures of about 0.1 to about 2 bar (preferably atmospheric pressure), and / or exposure to about 460 lux of ultraviolet / visible light, and / or relative humidity of about 5 to about 95% (preferably about 10 to about 40%).

[0048] Under such conditions, the compositions of the present invention may optionally be found to be less than about 15%, more preferably less than about 10%, and especially less than about 5% chemically degraded / separated and / or solid-state transformed. Those skilled in the art will appreciate that the above upper and lower limits of temperature and pressure represent the extremes of normal storage conditions, and that certain combinations of these extremes will not be experienced during normal storage (e.g., a temperature of 50°C and a pressure of 0.1 bar).

[0049] Such chemical and especially physical stability is very important in solid dosage forms such as powders used in the treatment of opioid overdose and the like.

[0050] It is well known that significant difficulties can arise when attempting to obtain solid compositions, such as powders, that are chemically and physically stable. In the case of the present invention, if the physical form of the compositions of the present invention changes under normal storage conditions (e.g., from a free-flowing powder to a clump that is difficult to expel), it is likely that the dose of opioid antagonist will not be reproducible (or even dispensed at all) when the composition is dispensed from or through a nasal applicator, which would seriously endanger the life of the subject.

[0051] For certain compositions (e.g., powders) of the present invention, exposure to atmospheric water can result in compositions with poor solid-state stability. For example, exposure to certain (e.g., relatively high) relative humidities can affect the physical form of the composition, for example, by deliquescence and / or by lowering the glass transition temperature of the composition and / or individual components of the composition, such as the carrier material, or in other ways.

[0052] Thus, the compositions of the present invention, and nasal applicators containing them, are preferably packaged in containers that substantially prevent the ingress of atmospheric water under normal storage conditions as defined above. Such containers may include packaging materials such as heat-sealed aluminum pouches and / or thermoformed plastics.

[0053] When the composition comprises alkyl sugars, suitable pharmaceutically acceptable solid carrier materials are therefore, for example, cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, cellulose acetate, hydroxypropylmethylcellulose (hypromellose, HPMC), hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), methylcellulose (MC), ethylhydroxyethylcellulose, carboxymethylcellulose (CMC), modified cellulose gum, microcrystalline cellulose and sodium carboxymethylcellulose; starches, such as rice starch, tapioca starch, wheat starch, and more particularly corn starch and potato starch; starch derivatives, such as pregelatinized starch, carboxymethyl starch, and moderately cross-linked starches, modified starches and sodium starch glycolate; dextrins, cyclodextrins, and maltodextrins. polysaccharides, including dextrins, such as linear or branched dextrins such as sucrose; powdered tragacanth; malt; gelatin; talc; waxy excipients, such as cocoa butter and suppository wax; polyols, such as solid polyethylene glycol; sugars, sugar alcohols, and saccharides, such as mannitol, maltitol, xylitol, sorbitol, lactose, glucose, galactose, sucrose, sucralose, trehalose, maltose, isomalt, and dextrose; acrylic polymers, such as carbomer and its derivatives; polyvinylpyrrolidone (povidone, PVP); cross-linked polyvinylpyrrolidone; polyethylene oxide (PEO); chitosan (poly-(D-glucosamine)); natural polymers, such as gelatin, sodium alginate, and pectin; scleroglucan; xanthan gum; guar gum; polyco-(methyl vinyl ether / maleic anhydride); and croscarmellose (e.g., croscarmellose sodium). Mention may also be made of hypromellose succinate (HPMCAS), copovidone and polyvinyl alcohol (PVA, or PVOH). Mixtures of any of the foregoing may also be used.

[0054] Thus, the composition according to the first aspect of the present invention can be compressed into a single unit dosage form, granulated into pellets or pills, but is preferably provided in the form of a dry, free-flowing powder. The compositions of the second and third aspects of the present invention are provided in the form of a dry, free-flowing powder. In the context of any aspect of the present invention, "dry" includes essentially free of water and other liquid solvents, including less than about 10%, such as less than about 5%, more preferably less than about 3%, such as less than about 2%, e.g., less than about 1% of the formulation is liquid, such as water.

[0055] Thus, the compositions of the present invention can be administered in the form of a plurality of particles, which particles individually and / or collectively consist of and / or comprise the compositions of the present invention. The compositions of the present invention can be prepared in the form of simple powder mixtures, powdered microspheres, coated powdered microspheres, lyophilized liposomal dispersions, or combinations thereof.

[0056] Whether in powder form or not, the amount of carrier material(s) that may be used in the compositions of the present invention typically ranges from about 5% to about 99.9% by weight, including about 10% by weight (e.g., about 25% by weight, including about 35% by weight) to about 85% by weight, including about 50% to about 75% by weight, based on the total weight of the composition, including up to about 99% by weight (e.g., up to 95% by weight or about 90% by weight).

[0057] Furthermore, whether in powder form or not, the compositions of the present invention can be prepared by standard techniques and using standard equipment known to those skilled in the art. In this regard, the compositions of the present invention can be combined with conventional pharmaceutical additives and / or excipients used in the art for the relevant preparations and incorporated into various types of pharmaceutical preparations using standard techniques (see, for example, Lachman et al., "The Theory and Practice of Industrial Pharmacy," Lea & Febiger, 2003). rdedition (1986), “Remington: The Science and Practice of Pharmacy”, Troy (ed.), University of the Sciences in Philadelphia, 21 st edition (2006), and / or “Aulton's Pharmaceutics: The Design and Manufacture of Medicines”, Aulton and Taylor (eds.), Elsevier, 4 th edition, 2013).

[0058] Dry powders can be prepared by mixing the opioid antagonist with a pharmaceutically acceptable carrier material and alkyl sugar, if present, and any other ingredients that may be included. Suitable techniques that can be used include simple dry blending, granulation (including dry granulation, wet granulation, melt granulation, thermoplastic pelletizing, spray granulation), extrusion / spheronization, or lyophilization.

[0059] Dry granulation methods are also well known to those skilled in the art and include any technique in which primary powder particles are agglomerated under high pressure, including, for example, slugging and roller compaction, as described below.

[0060] Wet granulation is well known to those skilled in the art and involves any technique involving agglomerating a mixture of dry primary powder particles with a granulation fluid comprising a volatile inert solvent such as water, ethanol, or isopropanol, alone or in combination, and optionally in the presence of a binder or binding agent. This technique may include forcing the wet mass through a sieve to produce wet granules, which are then dried, preferably to a loss on drying of less than about 3% by weight.

[0061] Those skilled in the art know that melt granulation includes any technique in which granules are obtained by adding a molten binder or a solid binder that melts during the process (these binder materials may contain pharmaceutically acceptable carrier materials). After granulation, the binder is solidified at room temperature. Thermoplastic pelletization is known to be similar to melt granulation, but uses the plastic properties of the binder. In both processes, the resulting agglomerates (granules) contain a matrix structure.

[0062] Extrusion / spheronization is well known to those skilled in the art to include any process involving dry mixing of ingredients, wet massing with a binder, extrusion, spheronization of the extrudate into uniformly sized spheroids, and drying.

[0063] Those skilled in the art know that spray granulation includes any technique involving the drying of a liquid (solution, suspension, melt) and simultaneously depositing granules in a fluidized bed.Therefore, this term generally includes any spray coating granulation technique, as well as the process in which foreign seeds (bacteria) are provided and granules are deposited on them, and the process in which indigenous seeds (bacteria) are formed in the fluidized bed by abrasion and / or crushing.The sprayed liquid covers the bacteria and helps further particle aggregation.Then, it is dried to form granules in the form of a matrix.

[0064] The term "lyophilization" includes lyophilization or cryodesication, and any low-temperature desolvation (e.g., dehydration) process in which a product is frozen, the pressure is reduced, and the frozen solvent (e.g., water) is removed by sublimation.

[0065] However, it is preferred that the compositions of the present invention be prepared by the process of spray drying.

[0066] It will be understood by those skilled in the art that spray drying includes any method of producing dry powders from liquids, including solutions or suspensions (including slurries), that involves using hot gases to rapidly dry and convert the liquid stream into solid particles that include vaporized solvent and solutes that were previously dissolved in the solution and / or particles that were previously suspended in the evaporated liquid.

[0067] Suitable spray drying equipment includes some form of atomization means, such as a spray nozzle, that disperses a liquid into a spray having a relatively uniform droplet size. Such means may include any means capable of producing a dry, free-flowing powder, and may include high-pressure swirl nozzles, rotating disks and / or atomizer wheels, high-pressure single-fluid nozzles, two-fluid nozzles, and / or ultrasonic nozzles.

[0068] The spray dryer may be a single effect or a multiple effect spray dryer and may include an integrated and / or external vibrating fluidized bed, a particle separator, and / or a collection means which may be a drum or a cyclone.

[0069] Spray drying can be used to produce compositions of the invention in the form of a powder, thereby encapsulating a substance in a carrier material or producing an amorphous complex of the active ingredient, carrier material and other ingredients.

[0070] In this regard, the compositions of the present invention in the form of a powder, particularly when produced by spray drying, can be considered to contain multiple particles, and the particles themselves are "monoparticulate" in nature. "Monoparticulate" includes particles that contain a homogeneous or heterogeneous mixture, in which the active ingredient is encapsulated in an amorphous state within a carrier material in the presence of other ingredients (e.g., an amorphous complex thereof). In this regard, such compositions of the present invention do not include mixtures in which particles of two or more separate, distinct components are mixed together, such as ordered or interactive mixtures in which relatively small particles of an active ingredient are associated with relatively large, separate, chemically distinct particles of a carrier material, as is often the case with inhaled drug delivery compositions (see, for example, Mehta, J. Drug Delivery, Art. ID 5635010, 1-19 (2018)).

[0071] Thus, the spray-dried compositions of the present invention are preferably amorphous in nature, comprising entirely and / or predominantly amorphous (e.g., greater than about 50% by weight, such as greater than about 90% or 95% by weight, including greater than about 99% by weight, such as greater than about 75% by weight, including greater than about 80% by weight), and are likely to yield pharmaceutical products that exhibit excellent shelf life, in terms of both physical and chemical stability, when stored under normal storage conditions as defined above.

[0072] According to a further aspect of the present invention there is provided a process for producing the composition of the present invention (in the form of a dry powder), the process comprising: i) mixing together the opioid antagonist, alkyl sugar (if present), and a pharmaceutically acceptable carrier material in a suitable volatile solvent; ii) spray drying the mixture of step i) to form a plurality of spray-dried particles.

[0073] Preferred volatile solvents include water or organic solvents such as lower alkyl alcohols (e.g., ethanol), haloalkanes, etc. Other solvents that may be mentioned include hydrocarbons (e.g., C 5-10 Alkanes), dimethylformamide, dimethylsulfoxide, ethyl acetate, acetone, etc. Mixtures of any of the foregoing solvents may also be used.

[0074] Preferably, the opioid antagonist, alkyl sugar (if present), and pharmaceutically acceptable carrier material are mixed together with a solvent to provide a solution that can be spray dried.

[0075] Particularly preferred pharmaceutically acceptable carrier materials which can be used to produce the spray-dried compositions of the invention (whether according to the first, second or third aspect of the invention) and which have the desirable properties described herein include sugars, more preferably disaccharides such as maltitol, trehalose, sucralose, sucrose, isomalt, maltose, and especially lactose (including β-D-lactose and α-D-lactose, especially α-D-lactose monohydrate); and / or any of the polymeric materials previously mentioned as suitable carrier materials (such as sodium carboxymethylcellulose, sodium starch glycolate, polyvinylpyrrolidone, and especially hydroxypropylmethylcellulose). and polymers comprising polysaccharides such as dextrins, in particular including cyclodextrins (e.g., α-, β-, and γ-cyclodextrins and their derivatives, such as 2-hydroxypropyl-γ-cyclodextrin, sulfobutylether β-cyclodextrin sodium salt, randomly methylated β-cyclodextrin, branched β-cyclodextrins, and the like, and especially 2-hydroxypropyl-β-cyclodextrin); and linear or branched dextrins such as maltodextrins classified by DE (dextrose equivalent) which may be 3 to 20 (the higher the DE value, the shorter the glucose chains), in particular maltodextrins having a DE of 6 to 15, such as 8 to 12.

[0076] Also included within the scope of the present invention are combinations of two or more of the above preferred materials.

[0077] The carrier material, whether a single carrier material or a combination of two or more carrier materials, is capable of producing the spray-dried composition of the present invention in powder form, and the composition preferably has a glass transition temperature (Tg) such that: (a) allows for the production of the composition in a hard and / or brittle, "glassy," amorphous, powder-like physical form that can be readily loaded into a nasal applicator or a drug reservoir and / or container described herein within or associated with such an applicator; and (b) to the extent that after such an applicator or reservoir is packaged as described herein and thereafter exposed to a high external temperature (e.g., up to about 50°C to about 80°C), the composition remains in the example glassy state instead of transforming into a more viscous or rubbery state and / or a crystalline state.

[0078] Such extreme external temperatures are often experienced inside vehicles (e.g., first responders') in warm and / or sunny climates, and such vehicles are frequently parked in the hot sun for extended periods of time, and the resulting heat can be enormous. If the Tg of the compositions of the present invention is low, the composition may transform into such a viscous / rubbery state after exposure to such high temperatures, which causes inefficient release of the composition (and also the dose of opioid antagonist) from the applicator or reservoir when the applicator is actuated.

[0079] In this regard, the lowest measurable Tg of the compositions of the present invention is preferably at least about 40°C, such as at least about 50°C, including at least about 55°C, including at least about 60°C, when measured at a relative humidity of up to about 35%, such as up to about 30%, including up to about 25% (e.g., up to about 20%, such as less than about 15%, e.g., less than about 10%). The term "lowest measurable Tg" includes the fact that the compositions of the present invention may contain particles that are heterogeneous in nature. In particular, when multiple carrier materials are used, the particles may contain isolated regions of carrier materials that may have individual and distinct Tg values, or complex mixtures thereof. It will be apparent to those skilled in the art that the value of the lowest measurable Tg has a strong impact on the physical stability of the composition.

[0080] When the carrier material comprises a combination of one or more disaccharides (as defined above) and one or more polymeric components (as defined above, particularly when the polymer is a dextrin), the relative amounts of these components in the combination can be tailored to ensure the required level of physical and / or chemical stability of the active ingredient while not lowering the Tg of the compositions of the present invention in a manner that affects physical stability. Depending on the active ingredient used, it has been found that a disaccharide:polymer (e.g., dextrin) ratio of about 50:1 to about 1:50 by weight, based on the total weight of the composition, can work. Preferred ratios are disaccharide:polymer (e.g., dextrin) ratios in the range of about 10:1 to about 1:40 (including up to about 1:30 or up to about 1:20), e.g., about 2:1 to about 1:10, more preferably about 1:1 to about 1:8, based on the total weight of the composition.

[0081] In particular, and as described below, we believe that the compositions of the present invention are spray dried, and (i) The chemical stability of opioid antagonists is significantly improved when produced by using disaccharides as carrier materials compared to monosaccharides such as mannitol, which is surprising since mannitol has previously been used in physical mixtures with opioid antagonists such as naloxone without any stability issues. (ii) When made using dextrins, such as cyclodextrins or maltodextrins, as the carrier material, they provide significantly improved physical stability when compared to other carrier materials.

[0082] (iii) However, the use of such dextrins causes unexpected chemical instability of the opioid antagonist. (iv) We found that the chemical instability could be overcome by spray drying the dextrin together with a disaccharide.

[0083] Thus, a particularly preferred combination of carrier materials includes a disaccharide, particularly trehalose, more preferably lactose, such as α-D-lactose monohydrate, and a dextrin, particularly a cyclodextrin, such as 2-hydroxypropyl-β-cyclodextrin, or a maltodextrin, such as maltodextrin 12DE. We have found that such combinations of carrier materials can be spray-dried in appropriate ratios with an opioid antagonist and an alkyl sugar to produce compositions of the invention that have both the desired physical and chemical stability under normal storage conditions, as defined above.

[0084] We have found that an amount of disaccharide of about 5% by weight (particularly about 10% by weight) to about 30% by weight, e.g., about 15% by weight to about 25% by weight, e.g., about 17% by weight to about 24% by weight, based on the total weight of the composition, provides the required level of chemical stability of an opioid antagonist such as naloxone while not lowering the Tg of the compositions of the present invention in a manner that affects physical stability. Accordingly, a suitable amount of dextrin is in the range of about 30% by weight to about 90% by weight, e.g., up to about 85% by weight, including up to about 80% by weight, particularly up to about 75% by weight, e.g., about 40% by weight to about 70% by weight, e.g., about 43% by weight to about 67% by weight, based on the total weight of the composition.

[0085] As described below, the compositions of the present invention exhibit surprisingly good bioavailability and quite surprisingly more rapid absorption, which likely results in a more rapid onset of action compared to related reference products (e.g., in the case of naloxone, Narcan nasal spray).

[0086] This is highly unexpected for several reasons: (a) Unlike the compositions of the present invention, which are solid, existing products such as Narcan present the opioid antagonist (in this case, naloxone) in a pre-dissolved state, ready for absorption; (b) In any event, naloxone and the other opioid antagonists described herein are known to be highly bioavailable and rapid-onset drugs when administered via the nasal mucosa. Thus, these compositions represent a therapeutic improvement over those already highly bioavailable and fast-acting.

[0087] As further described below, compositions of the present invention that include alkyl sugars have also been found to exhibit surprisingly good bioavailability and absorption rates compared to corresponding compositions that do not include alkyl sugars and / or contain different excipients known to act as surfactants. This is quite surprising, given that when tested ex vivo, such alkyl sugars tended to decrease the permeation of opioid antagonists such as naloxone through mucosal membranes, whereas different surfactants, including some listed below, tended to increase permeation.

[0088] Alkyl sugars that can be used in the compositions of the present invention include alkyl glycosides, which are 7-18Alkyl glycosides can be defined as any sugar linked to an alkyl group by a linkage. Thus, alkyl glycosides can include alkyl maltosides (such as dodecyl maltoside), alkyl glucosides, alkyl sucrosides, alkyl thiomaltosides, alkyl thioglucosides, alkyl thiosucroses, and alkyl maltotriosides. However, alkyl sugars are preferably sugar esters.

[0089] Sugar esters that can be used in the compositions of the present invention include trisaccharide esters such as raffinose esters, monosaccharide esters such as glucose esters, galactose esters and fructose esters, and / or preferably disaccharide esters such as maltose esters, lactose esters, trehalose esters, and especially one or more sucrose esters.

[0090] The sucrose esters used in the compositions of the present invention have a hydrophilic-lipophilic balance value of 6 to 20. The term "hydrophilic-lipophilic balance" (HLB) is a technical term that will be well understood by those skilled in the art (see, for example, "The HLB System: A Time-Saving Guide to Emulsifier Selection," published by ICI Americas Inc. in 1976 (revised in 1980); Chapter 7 (pages 20-21) of this document describes a method for determining the HLB value). The longer the fatty acid chain of the sucrose ester and the higher the degree of esterification, the lower the HLB value. A preferred HLB value is 10 to 20, more preferably 12 to 20.

[0091] Therefore, sucrose esters contain C 8-22 Saturated or unsaturated fatty acid esters, preferably saturated fatty acid esters, preferably C 10-18 Fatty acid esters, most preferably C 12Fatty acid esters are included. Particularly suitable fatty acids from which such sucrose esters can be formed include erucic acid, behenic acid, oleic acid, stearic acid, palmitic acid, myristic acid, and lauric acid. A particularly preferred such fatty acid is lauric acid. Commercially available sucrose esters include those sold under the registered trademarks Surfhope® and Ryoto® (Mitsubishi-Kagaku Foods Corporation, Japan).

[0092] The sucrose ester may be a diester or monoester of a fatty acid, preferably a monoester such as sucrose monolaurate. Those skilled in the art will understand that the term "monolaurate" refers to a monoester of lauric acid, and that the terms "lauric acid ester" and "laurate" have the same meaning and can therefore be used interchangeably. Commercially available sucrose monolaurate products are sometimes referred to as "sucrose laurate." Commercially available sucrose monolaurate (or sucrose laurate) products, such as Surfhope® D-1216 (Mitsubishi-Kagaku Foods Corporation, Japan), may contain small amounts of diesters and / or larger amounts of sucrose esters, as well as small amounts of other sucrose esters and free sucrose, and are suitable for use in the present invention. Those skilled in the art will understand that any reference herein to a specific sucrose ester includes commercially available products containing that sucrose ester as a major component.

[0093] Preferred sucrose esters contain only one sucrose ester, which means that a single sucrose ester (e.g., a commercially available sucrose ester product) contains a single sucrose ester as its / one major component (commercially available products may contain impurities, e.g., a monoester product may contain small amounts of diesters and / or higher esters, and such products may be considered to "contain only one sucrose ester" in the context of the present invention). As used herein, the term "major component" is understood to refer to the major component (e.g., more than about 50% by weight or volume, such as about 70% by weight / weight or volume / volume) in a mixture of sucrose esters, such as a common commercially available surfactant product, which is typically sold with a specific range of ester compositions.

[0094] A particularly preferred sucrose ester is sucrose monolaurate.

[0095] The amount of alkyl sugar in the compositions of the present invention ranges from about 0.1% by weight up to about 50% by weight, more specifically up to about 10% by weight, such as from about 0.5% by weight to about 5% by weight, and preferably from about 0.75% by weight to about 3% by weight (e.g., from about 1% by weight to about 2% by weight), based on the total weight of the composition.

[0096] In addition to any alkyl sugar component included within the compositions of the present invention, further, optional, additional excipients can be used.

[0097] Such additional excipients may comprise one or more (further) surfactants. Surfactants that may be mentioned include polyoxyl 8 stearate (Myrj® S8), polyoxyl 32 stearate (Gelucire® 48 / 16), polyoxyl 40 stearate (Myrj™ S40), polyoxyl 100 stearate (Myrj™ S100), and polyoxyl 15 hydroxystearate (Kolliphor® HS Polyoxyethylene alkyl ethers (e.g., Brij®) including polyoxyethylene esters (e.g., Myrj®) including polyoxyl cetostearyl ethers (e.g., Brij® CS12, CS20, and CS25), polyoxyl lauryl ethers (e.g., Brij® L9 and L23), and polyoxylstearyl ethers (e.g., Brij® S10 and S20), as well as polyoxyglycerides (e.g., Gelucire®) including lauroyl polyoxyglyceride (Gelucire® 44 / 14) and stearoyl polyoxyglyceride (Gelucire® 50 / 13), sorbitan esters (e.g., Myrj®) including sorbitan monopalmitate (Span® 40) and sorbitan monostearate (Span® 60), For example, polysorbates (Tweens™), including polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), and polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), and sodium lauryl sulfate; and monoacylglycerols (monoglycerides) such as 2-oleoylglycerol, 2-arachidonoylglycerol, monolaurin, glycerol monomyristate, glycerol monopalmitate, glyceryl hydroxystearate, and preferably, glycerol monostearate, glycerol monooleate (e.g., Cithrol®), and glycerol monocaprylate (e.g., Capmul®).

[0098] Other additional ingredients (excipients) that may be included in the compositions of the present invention include isotonic and / or osmotic agents (e.g., sodium chloride), sterols (or steroid alcohols) such as cholesterol and phytosterols (e.g., campesterol, sitosterol, and stigmasterol); antioxidants (e.g., α-tocopherol, ascorbic acid, potassium ascorbate, sodium ascorbate, ascorbyl palmitate, butylated hydroxytoluene, butylated hydroxyanisole, dodecyl gallate, octyl gallate, methylparaben, methylparaben, methylparaben); glycerol, propyl gallate, ethyl oleate, monothioglycerol, vitamin E succinate, polyethylene glycol, or thymol; chelating (complexing) agents (e.g., edetic acid (EDTA), citric acid, tartaric acid, malic acid, maltol, and galactose); preservatives (e.g., benzyl alcohol, boric acid, parabens, propionic acid, phenol, cresol, or xylitol); viscosity modifiers or gelling agents (such as cellulose derivatives including hydroxypropyl cellulose, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, and the like, starch and modified starches, colloidal silicon dioxide, aluminum metasilicate, polycarbophil (e.g., Noveon®), carbomer (e.g., Carbopol®), and polyvinylpyrrolidone); mucoadhesive polymers such as carboxymethylcellulose, modified cellulose gum, and sodium carboxymethylcellulose (NaCMC); starch derivatives such as moderately crosslinked starch, modified starch, and sodium starch glycolate; crosslinked polyvinylpyrrolidone. Acrylic polymers such as lolidone, carbomer and its derivatives (polycarbophil, Carbopol®, etc.); polyethylene oxide (PEO); chitosan (poly-(D-glucosamine)); natural polymers such as gelatin, sodium alginate, pectin; scleroglucan; xanthan gum; guar gum; polyco-(methyl vinyl ether / maleic anhydride); and croscarmellose (e.g., croscarmellose sodium); pH buffers (e.g., citric acid, maleic acid, malic acid, or glycine); colorants;Penetration enhancers (e.g., isopropyl myristate, isopropyl palmitate, pyrrolidone, or tricaprylin); other lipids (neutral and polar); and aromatic carboxylic acids such as benzoic acid, e.g., toluic acid or salicylic acid, optionally substituted with one or more groups selected from methyl, hydroxyl, amino, and / or nitro.

[0099] The total amount of such "additional" excipients (including one or more surfactants that are not alkyl sugar(s)) present (or may be present) in the compositions of the present invention may be up to about 15% by weight (e.g., about 10% by weight), such as up to about 5% by weight, based on the total weight of the composition.

[0100] Those skilled in the art will understand that if any additional optional ingredients are included in the compositions of the present invention, the nature of those ingredients and / or the amounts of those ingredients included should not adversely affect the Tg of the composition for the reasons discussed above. In this regard, when the compositions of the present invention are made by spray drying, such optional ingredients can be incorporated into the spray drying process (i.e., mixed together with the opioid antagonist, optional alkyl sugar, and pharmaceutically acceptable carrier material in a suitable volatile solvent and then spray-dried), or can be included separately in the spray-dried particles.

[0101] According to a further aspect of the present invention there is provided a composition of the present invention for use in human and veterinary medicine, particularly in the treatment of substance overdose, such as opioids, including opiates.

[0102] Overdose is understood in the art to include what occurs when an individual ingests a substance of abuse, such as an opioid, in larger amounts than they can physically tolerate, resulting in central nervous system and respiratory depression (in the case of opioids), hypoxia, miosis, and apnea, one or more of which can result in death if not promptly treated (see above).

[0103] According to a further aspect of the present invention, there is provided a method for treating substance (e.g., opioid) overdose, which method of treatment comprises administering to a patient suffering from such a condition a composition of the present invention.

[0104] "Treatment" of substance (e.g., opioid) overdose includes therapeutic, symptomatic, and palliative treatment, as well as prevention or diagnosis of such overdose (i.e., when an overdose is suspected), as the use of compositions of the invention in treating drug overdose may reverse or prevent the onset of the aforementioned opioid overdose symptoms.

[0105] When administering compositions of the invention that include a partial opioid antagonist, such as buprenorphine, care must be taken to ensure that the patient has overdosed on an opioid (e.g., not a benzodiazepine) and / or that the patient is physically addicted to opioids.

[0106] Opioid antagonists can also be administered for use in treating conditions mediated by endogenous opioid agonists (e.g., endorphins), which can be collectively classified as "endorphin-mediated hedonia," as manifested by addictive behaviors (e.g., excessive eating (bulimia), drinking (alcoholism), exercise, sex, gambling, etc.).

[0107] Thus, according to a further aspect of the present invention, there is provided a method for treating addictions and / or addictive behaviors mediated by activation of endogenous opioid agonists such as endorphins (including binge eating, alcoholism, and addictions to exercise, sex, gambling, etc.), which method of treatment comprises administering a composition of the present invention to a patient suffering from or susceptible to the relevant condition.

[0108] In the case of such addictions and addictive behaviours, "treatment" includes the palliative and especially symptomatic treatment of such conditions, as well as the prevention of the onset (prophylaxis) and diagnosis of such conditions.

[0109] The compositions of the present invention can be administered intranasally by any suitable intranasal administration means known to those skilled in the art, such as a nasal applicator or dispenser, which allows for the administration of an appropriate dose of opioid antagonist in the form of a composition of the present invention to the nasal cavity.

[0110] Thus, such applicator means must be capable of containing and storing the composition of the present invention itself, or be capable of being attached to a reservoir / container that contains and stores the composition of the present invention, such as in powder form, and be capable of doing so without significant loss of the physical and chemical integrity of the composition, for example, due to the ingress of water. In this way, the composition is ready for use when the applicator device is actuated by the end user, whereupon the applicator delivers a composition (e.g., a powder) comprising an appropriate dose of an opioid antagonist, as defined herein, to the nasal mucosa of the subject.

[0111] Suitable applicator means have been described in the prior art. When used with the compositions of the present invention (especially those in powder form), such compositions may be loaded into a reservoir attached to or forming part of such applicator means, where they are contained until the applicator means, or dispenser, is actuated. Hereinafter, the terms "applicator," "dispenser," "device," "applicator means," "dispensing means," "applicator device," and "dispensing device" may be used interchangeably and mean the same thing.

[0112] Such applicator means may therefore also include a mechanism for expelling the powder formulation from the reservoir via an outlet means, which may include a suitably shaped nozzle or the like, any size sized for placement within a human nostril.

[0113] Therefore, the applicator must be able to provide a reproducible and sufficient amount of the powder formulation in a single administration step (and in a manner that does not require "priming" the device) to provide a therapeutic dose of the opioid antagonist.

[0114] Nasal applicators / inhalation devices that can be used to administer the compositions of the present invention in powder form can include multi-dose applications such as metered dose inhalers (MDIs), dry powder inhalers (DPIs; including low, medium, and high resistance DPIs) and soft mist inhalation devices (SMIs), which can be adapted based on technology known in the art of delivery of active ingredients to the lungs.

[0115] In an MDI, the compositions of the present invention can form a stable suspension when suspended in a solvent, such as a propellant typically used therein, and the propellant must have sufficient vapor pressure to form an aerosol upon actuation of the delivery device (e.g., a hydrocarbon, a fluorocarbon, a hydrogen-containing fluorocarbon, or a mixture thereof).

[0116] However, it is preferred that the nasal applicator is a single dose applicator from which the composition is dispensed upon actuation and then discarded after use.

[0117] In this regard, suitable applicator means or devices include those described in US Pat. No. 6,398,074, US Pat. No. 6,938,798, or US Pat. No. 9,724,713, the relevant disclosures of which are incorporated herein by reference. Figures 1 and 2 of the present application are based on Figures 1 and 2 of US Pat. No. 6,398,074, respectively, and Figures 3-7 are based on Figures 19-23 of US Pat. No. 9,724,713, respectively. Both are illustrative of applicators that can be used to administer the compositions of the present invention intranasally.

[0118] In Figure 1, the device comprises a body top / dispenser head 1 incorporating an outlet channel 40 (i.e., part of the aforementioned "exit means") and gripping means 60 that allow a user to actuate the device. Attached to the inside of body top / dispenser head 1 is an element, the assembly of which is designated by reference numeral 2, that incorporates a reservoir 10 and an air chamber 22 for an air blast 20. This element 2 may be produced integrally with body 1. A body bottom 3 is also provided to be slidable relative to body top 1 and relative to element 2, and upon which a user applies a pressure force to actuate the device.

[0119] Reservoir 10 contains a single dose of the composition of the present invention. Reservoir 10 has an air inlet 11 and a product outlet 15. A product retention device 12 including an air permeable grid is positioned within air inlet 11 to retain the product within reservoir 10 until the composition is dispensed. Product outlet 15 is blocked, preferably in a sealing manner, by a closure ball 16, which is removed from its blocking position by the flow of air when the applicator is actuated and product is dispensed.

[0120] When the user actuates the device, pressure is applied to the plunger 25 such that the piston 21 compresses the air 20 contained in the chamber 22. Because the grid 12 is permeable to air, the compression of the air in the chamber 22 creates an air blast which is transmitted to the reservoir 10 and, consequently, to the closure ball 16 blocking the product outlet 15.

[0121] The dimensions of the closure ball 16 and its fixation at the reservoir product outlet 15 are such that when a minimum predetermined pressure is created through the reservoir 10 by a blast of air 20, the ball 16 is removed from its blocking position.

[0122] The pre-compression created by the closing ball 16 ensures that when the ball is removed from its blocking position, the energy stored in the user's hand is such that the piston 21, integral with the plunger 25, is propelled within the chamber 22, thereby creating a powerful blast of air 20, i.e., an airflow suitable for finely atomizing a dose of the composition of the invention.

[0123] Once this minimum pressure is reached, the ball moves rapidly towards the outlet channel 40 of the device and the flow of air 20 created by the blast expels substantially all of the dose of the composition of the present invention contained within the reservoir 10.

[0124] Preferably, the outlet channel 40 has a diameter larger than that of the closure ball 16 to allow the dose of product to be discharged through the outlet channel 40 by flowing around the ball 16. As shown in Figure 2, which represents the same device after actuation, the channel 40 is provided with means 41 to stop or lock the ball 16 to prevent discharge of the ball from the device when the product is being discharged.

[0125] Further embodiments that can be used to administer the compositions of the present invention intranasally are provided in column 7, line 50 to column 8, line 61 and Figures 19 to 23 of US 9,724,713, which are reproduced as Figures 3 to 7 of the present application.

[0126] In this embodiment, the reservoir 10 is secured within a body top / dispenser head 1 which includes a dispenser outlet channel 40 (i.e., part of the "exit means" previously mentioned) having a gripping means or finger rest 60 which allows a user to actuate the device. A radial shoulder 37 (see FIG. 5) of the body top / dispenser head 1 advantageously defines the assembly location of the reservoir 10 within the body top / dispenser head 1.

[0127] The mechanical opening system comprises a set of rods 61, 62, and when the device is actuated, a second rod portion 62 is pushed against this first rod portion 61. At the end of their actuation stroke, i.e. in the dispensing position, the set of rods 61, 62 cooperate with the closure element 16, which is spherical, in particular a ball as in the first embodiment above, and mechanically eject it from the closed position.

[0128] In this embodiment, the piston 21 is separate from the first rod portion 61 and slides against both the air chamber 22 and a cylindrical surface 614 fixed to the first rod portion 61. Figure 7 is a perspective view of the air expeller of the device of Figures 3-6 in a rest position.

[0129] The air chamber 22 may therefore be cylindrical and in a rest position communicate with the surrounding air by means of flutings or grooves 615 formed in said cylindrical surface 614 and cooperating with the piston 21 in particular in the rest position. The piston 21 therefore comprises an inner lip 215 which slides in an airtight manner on the cylindrical wall 614 during actuation and which cooperates with said flutings 615 in the rest position. The piston 21 also comprises an axial extension 216 which cooperates with an upper edge 251 of a pusher element 25 (called a "plunger" in the first embodiment) which moves said piston 21 in the air chamber 22 during actuation.

[0130] The retaining member 42 is extended downwardly by an axial extension 43 which contacts the upper axial end 610 of the first rod portion 61 during actuation.

[0131] Furthermore, in this embodiment there is no outer body, only a cover 27 assembled onto the lower axial edge of the air chamber 22 .

[0132] A spring 80 is provided between the radial flange 225 of the air chamber 22 and the first rod portion 61 and the portion forming the cylindrical surface 614 so that the air expeller automatically returns to its rest position after actuation.

[0133] The principle of operation is as follows: In the rest position of Figure 3, the reservoir 10 is sealed closed by the retaining member 42 and the closure element / ball 16. The air expeller is open to the atmosphere by cooperation between the inner lip 215 of the piston 21 and the fluting 615 of the cylindrical surface 614.

[0134] When it is desired to actuate the device, the user pushes the pusher element 25. During this first stroke, the inner lip 215 of the piston leaves the fluting 615 and comes into airtight cooperation with the cylindrical surface 614, thereby closing the air chamber 22. At the same time, the upper edge 251 of the pusher element 25 contacts the axial extension 216 of the piston 21, and the upper axial end 610 of the first rod portion 61 contacts the axial extension 43 of the retaining member 42.

[0135] However, as can be seen in FIG. 4, the upper axial end 621 of the second rod portion 62 is still not in contact with the rounded surface 55 of the closure element / ball 16 .

[0136] Continued actuation therefore simultaneously moves the piston 21 within the air chamber, thereby compressing the air contained therein and moving the retaining member 42 away from the position that closes the reservoir 10. When the second rod portion 62 contacts the rounded surface 55 of the closure element / ball 16, this closure element / ball is mechanically expelled from its closed position so that the composition can be expelled under the influence of the air compressed by the air expeller.

[0137] The dispensing position is shown in Figure 5. As can be seen in Figure 5, the retaining member 42 can move away from the first rod portion 61 while the composition is being expelled under the influence of compressed air provided by the air expeller. In this position, the closure element / ball 16 is expelled from the reservoir 10 so that fluid or powder can be dispensed under the influence of compressed air. The closure element / ball 16 therefore jams into the spline 3 of the top body / dispenser head 1, which in particular prevents any risk of the closure element / ball 16 being expelled from the top body / dispenser head 1.

[0138] As shown in FIG. 6 , when the user releases the device, the spring 80, which was compressed during actuation, returns the first rod portion 61 toward its rest position. This creates a suction force that draws the closure element 16 and the retaining member 42 toward or near their closed position. This therefore blocks a new suction path, while leaving the empty reservoir assembled on the air expeller to prevent contamination during its automatic return to the rest position. However, the piston 21 remains in its dispensing position as a result of friction with the air chamber 22 and the suction force created within the reservoir 30, as the cylindrical surface 614 slides over the inner lip 215 until the inner lip once again cooperates with the fluting 615. At this point, the air chamber 22 is again in communication with the ambient air, and the suction force generated by the return to the rest position is no longer created. Therefore, the piston 21 also retracts toward its rest position. This allows the reservoir to be closed after use.

[0139] Optionally, the unit formed by the top body / dispenser head 1 and the empty reservoir 10 can be removed from the air expeller and replaced with a new unit containing a full reservoir.

[0140] Suitable applicator devices that can be used include those available from Aptar Pharma, France (UDS Monopowder).Other examples of applicator devices that can be used in combination with the compositions of the present invention (especially those in powder form) include those described in U.S. Patent Application No. 2011 / 0045088A, U.S. Patent No. 7,722,566 (see, for example, Figures 1 and 7) and U.S. Patent No. 5,702,362 and International Patent Application No. 2014 / 004400, the relevant disclosures of which are incorporated herein by reference.

[0141] According to a further aspect of the present invention, there is provided a process for manufacturing an applicator device comprising a composition of the present invention, the process comprising the step of loading said composition into a reservoir within or associated with said applicator device.

[0142] According to another aspect of the present invention there is provided an applicator and / or dispenser device comprising a composition of the present invention in powder form and suitable for dispensing the powder, the applicator / dispenser device comprising: an outlet through which the composition of the present invention is dispensed; a means for generating an external force (e.g., airflow) upon actuation of the device by a user; at least one (optionally replaceable) reservoir containing the composition of the present invention, which is in, or can be placed in, direct or indirect communication with the dispenser outlet; a displaceable sealing means in the device and / or reservoir for retaining the composition in the reservoir until the composition is dispensed; and A mechanical opening system which cooperates with the sealing means so that the composition of the present invention is mechanically expelled by the force application means when the device is actuated.

[0143] According to yet another aspect of the present invention there is provided an applicator and / or dispenser device comprising a composition of the present invention in powder form and suitable for dispensing the powder, the applicator / dispenser device comprising: Dispenser outlet, an air expeller for generating a flow of air during actuation of the device, the air expeller including a piston that slides within the air chamber between a rest position and a dispensing position; The piston slides in an airtight manner within the air chamber. at least one reservoir containing a dose of the composition of the present invention, the reservoir comprising an air inlet connected to said air expeller; a composition outlet connected to the dispenser outlet; the air inlet includes a displaceable sealing means (e.g., a retaining member) for retaining the composition within the reservoir until the composition is dispensed; The composition outlet is closed by a closure element fitted to the composition outlet of the reservoir. the device further includes a mechanical opening system that cooperates with the closure element to mechanically eject the closure element from the closed position during actuation of the device; and The piston of the air expeller cooperates in a non-airtight manner with the air chamber when in a rest position.

[0144] In the latter aspect of the invention, it is preferred that: (i) the air chamber in which the piston slides in an airtight manner is substantially cylindrical; (ii) the closure element is press-fit onto the composition outlet of the reservoir; (iii) the air chamber is in communication with the atmosphere in a stationary position; and / or (iv) the piston includes an inner lip adapted to cooperate with a cylindrical surface, the cylindrical surface including fluting that cooperates in a non-airtight manner with the inner lip of the piston in its rest position;

[0145] Such an applicator or dispensing device can provide a suitable and reproducible powder spray pattern and / or geometric plume shape that allows for efficient delivery of the powder to the nasal cavity (e.g., nostrils).

[0146] In the composition of the present invention, the average particle size can be presented as the average diameter by weight, number, or volume.As used herein, the term "weight-based average diameter" is understood by those skilled in the art to include the average particle size being characterized and defined by the particle size distribution by weight, that is, the distribution in which the existing fraction (relative amount) in each size class is defined as the weight fraction, for example, by sieving (for example, wet sieving).The term "volume-based average diameter" has a similar meaning to the weight-based average diameter, but is understood by those skilled in the art to include the average particle size being characterized and defined by the particle size distribution by volume, that is, the distribution in which the existing fraction (relative amount) in each size class is defined as the volume fraction, for example, measured by laser diffraction.As used herein, the term "number-based average diameter" is understood by those skilled in the art to include the average particle size being characterized and defined by the particle size distribution by number, that is, the existing fraction (relative amount) in each size class is defined as the number fraction, for example, measured by microscopy. Other instruments well known in the art may be used to measure particle size, such as those sold by Malvern Instruments, Ltd (Worcestershire, UK), Sympatec GmbH (Clausthal-Zellerfeld, Germany), and Shimadzu (Kyoto, Japan).

[0147] In the context of the present invention, those skilled in the art will understand that to enable intranasal administration, powders typically have a volumetric mean diameter (VMD) in the range of about 5 μm (e.g., about 10 μm) up to about 1,000 μm (e.g., up to about 500 μm). Depending on the applicator device used, the VMD can range from about 10 μm to about 100 μm, such as from about 20 μm to about 60 μm.

[0148] Preferred particle size distributions may also include those in which d10 is greater than about 3 μm, such as greater than about 10 μm, to less than about 75 μm (e.g., up to about 50 μm), and d90 is from about 80 μm to about 1,000 μm, such as less than about 100 μm (e.g., about 500 μm). Those skilled in the art will understand that the parameter "d10" (or "Dv(10)") refers to the size (or diameter) in a particle size distribution below which 10% of the total volume of material in a sample falls. Similarly, "d90" (or "Dv(90)") refers to the size below which 90% of the material falls.

[0149] Powders having particle size diameters and / or VMDs within the above ranges include bulk VMDs and / or emitted VMDs, i.e., the particle size distributions when initially loaded into and / or discharged from the device, respectively.

[0150] Particle size can be measured by standard equipment such as dry (or wet) particle size measurement techniques, including dry dispersion techniques available from manufacturers such as Sympatec and Malvern.

[0151] Preferred particle shapes include spherical or essentially spherical, meaning that the particles have an aspect ratio of less than about 20, more preferably less than about 10, such as less than about 4, and especially less than about 2, and / or at least about 90% of the particles may have a variation in radius (measured from the center of gravity to the particle surface) of less than or equal to about 50% of the mean value, such as less than or equal to about 30% of the mean value, for example less than or equal to about 20% of that value.

[0152] Nevertheless, particles can be of any shape, including irregularly shaped (e.g., "raisin" shaped), needle-shaped, disk-shaped, or rectangular shaped particles. For non-spherical particles, size can be given as the size of a corresponding spherical particle of, for example, the same weight, volume, or surface area.

[0153] The spray angle of the powder composition of the present invention emitted (dispensed) from the applicator and / or dispenser device should preferably be less than about 90°.

[0154] The compositions of the present invention can be formulated with additional active ingredients known to treat opioid withdrawal symptoms, such as lofexidine, and / or partial opioid antagonists used in the treatment of opioid dependence, such as buprenorphine (see above).

[0155] Thus, co-administration of at least one of the aforementioned (preferably full) opioid antagonists along with such opioid withdrawal treatments (such as lofexidine or buprenorphine) can help to negate the intense withdrawal symptoms that may be observed when administering the compositions of the present invention in the absence of such compounds.

[0156] Thus, the compositions of the invention may be provided together with a compound suitable for use in treating opioid withdrawal symptoms (such as lofexidine or buprenorphine, or a pharmaceutically acceptable (e.g., HCl) salt of either compound, where the latter compound / treatment is included in the composition (i.e., presented as a single pharmaceutical composition containing both active ingredients). Alternatively, the compositions of the invention may be co-administered with a separate composition comprising a compound suitable for use in treating opioid withdrawal symptoms (such as lofexidine or buprenorphine) or a salt thereof.

[0157] Thus, there is further provided a pharmaceutical preparation comprising a composition of the invention as defined above, which composition further comprises a compound suitable for use in the treatment of opioid withdrawal symptoms (such as lofexidine or buprenorphine) or a pharmaceutically acceptable salt thereof; such a preparation is hereinafter referred to as a "combination preparation".

[0158] Further provided is a process for preparing the combination preparation as defined above, which process comprises associating an opioid antagonist as defined above and a compound suitable for use in treating opioid withdrawal symptoms (e.g., lofexidine, buprenorphine or a salt thereof), along with other components of the composition of the invention, and optionally loading them into a container for use in or with (e.g., attached to) an applicator device as described above.

[0159] In such cases, the combined preparation may have the same or similar physical attributes as those described above for the composition of the present invention that does not include a compound suitable for treating opioid withdrawal symptoms, the relevant disclosures of which are incorporated herein by reference.

[0160] In a further aspect of the present invention, there is also provided a kit of parts comprising the following components (A) and (B): (A) a composition of the present invention, and (B) a pharmaceutical composition comprising a compound suitable for use in treating opioid withdrawal symptoms (e.g., lofexidine or buprenorphine) or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable diluent or carrier; Compositions (A) and (B) are optionally packaged or presented for packaging in separate containers, which are for use in or with (e.g., attached to) the same or a separate applicator device suitable for administering the compositions to the nasal cavity, e.g., as described above.

[0161] In such cases, the pharmaceutical composition constituting the opioid withdrawal symptom treatment described in (B) above can have the same or similar physical attributes as those described above for the compositions of the present invention, including those described above for (A) above. For example, the pharmaceutical composition constituting the opioid withdrawal symptom treatment can be presented in the form of a powder containing particles having a particle size similar to those described above for the compositions of the present invention.

[0162] According to a further aspect of the present invention there is provided a method of making the kit of parts as defined above, comprising associating component (A) as defined above with component (B) as defined above, thus rendering the two components suitable for administration in combination with one another.

[0163] As alluded to above, "associating" two components with one another means that components (A) and (B) of a kit of parts are: (i) may be provided as separate formulations (i.e., independently of each other) that are subsequently combined for use in combination with one another in a combination therapy; or (ii) may be packaged and presented together as separate components of a "combination pack" for use in combination with each other in combination therapy.

[0164] therefore, (I) one of components (A) and (B) as defined herein, (II) A kit of parts is further provided, comprising the two components together with instructions for using the component in combination with the other of the two components.

[0165] The kits of parts described herein may contain more than one formulation containing an appropriate amount / dosage of an opioid antagonist / salt, and / or more than one formulation containing an appropriate amount / dosage of a compound suitable for treating opioid withdrawal symptoms, to provide for repeated administration. When more than one formulation (containing any of the active compounds) is present, such formulations may be the same or different with respect to the dosage, chemical composition(s), and / or physical form(s) of any of the compounds.

[0166] With respect to the kits of parts described herein, "administration in combination with" includes sequential, separate and / or simultaneous administration of respective formulations comprising an opioid antagonist (or a salt thereof) and a compound suitable for treating opioid withdrawal symptoms (or a salt thereof) to treat the associated conditions.

[0167] Thus, in relation to a combination product according to the invention, the term "administration in combination with" includes administration together or sufficiently close in time (optionally repeatedly) to allow for a greater beneficial effect on the patient than if the two components of the combination product were administered alone (optionally repeatedly) without the other component. Determining whether a combination provides a greater beneficial effect over the course of treatment of the relevant condition will depend on the condition being treated or prevented, but can be routinely accomplished by one of ordinary skill in the art.

[0168] After the emergency of treating an acute opioid overdose has been addressed, an additional composition containing a compound suitable for treating opioid withdrawal symptoms (e.g., lofexidine, or more preferably, buprenorphine or a salt thereof) can be administered as needed or desired. Such compositions may or may not be similar in form to the compositions of the present invention (in this regard, the relevant disclosures of which are incorporated herein by reference) (e.g., sublingual formulations).

[0169] When the compound suitable for treating opioid withdrawal symptoms is buprenorphine, a suitable dosage may range from about 1 mg to about 32 mg, more preferably from about 5 mg to about 20 mg, calculated as the free base.

[0170] When the compound suitable for treating opioid withdrawal symptoms is lofexidine, a suitable dosage (e.g., daily dose) may be in the range of about 0.1 mg to about 3 mg, such as about 0.5 mg to about 2 mg, calculated as the free base.

[0171] When the word "about" is used herein in the context of quantities, e.g., absolute amounts such as dosage, weight, volume, size, diameter, or relative amounts (including concentrations and ratios) of individual components in a composition or a component of a composition, time frames, and parameters such as temperature, pressure, relative humidity, etc., it will be understood that such variables are approximate and thus can vary by ±10%, e.g., ±5%, and preferably ±2% (e.g., ±1%) from the actual numerical values ​​specified herein. This is true even when such numerical values ​​are expressed as percentages (e.g., "about 10%" can mean ±10% around the number 10, which can be anywhere from 9% to 11%).

[0172] The compositions of the present invention have the advantage of being able to be stored over a wider temperature range than prior art compositions, including those commercially available (e.g., Narcan for naloxone). Thus, the compositions of the present invention can be exposed to low temperatures (e.g., sub-freezing) without affecting the amount of opioid antagonist administered to a subject. Furthermore, the compositions of the present invention can have the advantage of being more physically and chemically stable at high temperatures than such prior art compositions.

[0173] The compositions of the present invention have the additional important advantage of providing a higher bioavailability of the opioid antagonist compared to prior art compositions, including those commercially available (e.g., Narcan for naloxone). The compositions of the present invention provide this higher bioavailability along with more rapid absorption, which is likely to result in a more rapid onset of action than such prior art and / or commercially available compositions, thus fulfilling an important and serious medical need.

[0174] The compositions, pharmaceutical formulations, uses and methods described herein, in treating the above-mentioned conditions, whether for use in treating opioid overdose (or binge eating or alcoholism), may also have the advantage that they may be more convenient for first responders, physicians and / or patients, more effective, less toxic, have a broad spectrum of activity, be more potent, have fewer side effects, have less inter-patient variability, or have other useful pharmacological properties over similar formulations or methods (treatments) known in the prior art.

[0175] The present invention is illustrated, but in no way limited, by the following examples and with reference to the accompanying figures, in which Figures 1 to 7 represent actuator devices that can be used to dispense the compositions of the present invention, Figures 8 and 9 show the permeation of naloxone and nalmefene, respectively, through porcine nasal tissue in an ex vivo model, and Figures 10 and 11 show the mean naloxone plasma concentrations (linear scale) versus time per treatment obtained in clinical trials over different time periods.

[0176] Example 1 Spray drying of opioid antagonists with various carbohydrates Naloxone HCl dihydrate (1.199 g; Johnson Matthey, UK) or nalmefene HCl (0.600 g; Santa Cruz Biotechnology Inc., USA) and naltrexone HCl (0.600 g; Mallinckrodt Inc., USA) were mixed separately with different sugars (5.088 g for naloxone and 2.554 g for nalmefene and naltrexone) used as carrier materials for the compositions and purified water for washing (56.58 g for naloxone and 28.29 g for nalmefene and naltrexone), and the mixture was fed into a spray dryer according to the following general procedure.

[0177] The solid components were weighed into a beaker equipped with a magnetic stir bar, dissolved in water, and fed into a spray dryer (ProCepT, Belgium) equipped with an ultrasonic nozzle operating at 25 kHz. The spray dryer feed rate was set at 3.0 g / min, the inlet temperature was set at 180 °C, the gas flow rate was set at 300 L / min, and the cyclone gas was set at 1.5 bar.

[0178] The resulting spray-dried powder was collected and packed into a device suitable for nasal powder administration (a disposable single-shot nasal uni-dose device; UDS Monopowder, Aptar Pharma, France) with a fill weight of 23 mg (in the case of naloxone, this constituted a single dose of 4 mg naloxone (calculated as the HCl salt)). The devices were placed in heat-sealed aluminum pouches and then stored at 40°C and 75% relative humidity (RH) for 6 months.

[0179] The chemical composition of the spray-dried mixture after storage and the amount of powder emitted from the device after actuation were determined.

[0180] The stability of naloxone after 6 months (6M), expressed as percentage of related substances (%RS), for different sugars is summarized in Table 1 below. The initial values ​​of %RS were less than 0.1% for all samples. [Table 1]

[0181] Unexpectedly, certain monosaccharides, such as mannitol, which had previously been used in physical mixtures with naloxone, were found to be incompatible (in terms of naloxone's chemical stability) when used in this spray-drying process, in contrast to disaccharides, such as lactose, which are generally compatible.

[0182] Furthermore, polysaccharides known to have higher Tg tended to produce higher emitted powder doses. Physical changes as a result of the low Tg caused the powder within the device to cake and clump.

[0183] Similar trends were observed for nalmefene and naltrexone (see Table 2 below, with initial %RS values ​​shown in parentheses). [Table 2]

[0184] Example 2 Physical stability of spray-dried powders To assess physical stability and mitigate the risk of crystallization during storage, differential scanning calorimetry (DSC) was used to determine the glass transition temperature (Tg) and is shown in Table 3 below.

[0185] Compositions were prepared generally according to the procedures described in Example 1 above, using mannitol, trehalose and lactose as carrier materials.

[0186] For lactose, the true Tg was measured, as well as the Tg of formulations equilibrated at 25°C under four different RH conditions (RH 10%, 20%, 30%, and 40%) (except 30% was not recorded). For mannitol and trehalose, the Tg was measured as received ("ambient") and after drying ("dry").

[0187] For dried samples, the lids of the DSC ampoules were automatically punched just before the start of the DSC run, introducing a hole approximately 0.3 mm in diameter. The purpose was to allow any remaining water to evaporate before the glass transition temperature of the dried formulation was reached. Therefore, this Tg value corresponds to the true Tg, without interference from available plasticizers such as water.

[0188] For samples equilibrated at various RH values, the DSC lid was kept airtight throughout the DSC run. Samples were prepared as described above. [Table 3]

[0189] The use of trehalose or lactose as carrier materials resulted in a completely amorphous composition, in contrast to mannitol, which appeared to crystallize in the spray dryer, as no Tg was found and the moisture content was less than 1%.

[0190] Example 3 Ex vivo evaluation of nasal mucosal absorption of naloxone and nalmefene An ex vivo model of nasal mucosal absorption was established using excised porcine nasal tissue using a standard static diffusion (Franz) cell setup.

[0191] Solutions containing naloxone HCl dihydrate, nalmefene HCl, benzalkonium chloride (Sigma-Aldrich Sweden AB), sucrose monolaurate (IMCD Nordic AB) and / or polysorbate 80 (Croda Nordica AB) were prepared by standard techniques to provide formulations according to Table 4 below. Potassium phosphate buffer (Sigma-Aldrich Sweden AB) was added to obtain the pH listed in Table 4 below. [Table 4]

[0192] After 7 hours, diffusion through the tissue was measured and permeation was reported as the mean (three replicates) cumulative transport (μg / cm ) for naloxone and nalmefene in Figures 8 and 9, respectively. 2 , standard deviations are also given).

[0193] For both naloxone and nalmefene, slightly higher apparent permeability coefficients (Papp) were observed in formulations 7 and 8, which contained polysorbate 80 and more pH buffer, respectively. No corresponding absorption enhancement was observed in the case of benzalkonium chloride or sucrose monolaurate.

[0194] Example 4 Naloxone-containing composition B Using the general procedure described in Example 1, a spray-dried composition was made from naloxone HCl dihydrate (1.199 g), and α-D-lactose monohydrate (5.026 g; DFE Pharma Germany), sucrose monolaurate D-1216 (0.062 g; Mitsubishi-Kagaku Foods Corporation, Japan).

[0195] Composition B contained a single dose of 4 mg of naloxone (calculated as the HCl salt).

[0196] The devices were placed in heat-sealed aluminium pouches (Protective Packaging, UK) before use.

[0197] Geometric particle size distribution (PSD) was measured using a Malvern Mastersizer 2000 (Malvern Panalytical Ltd, UK), and aerodynamic particle size distribution (aPSD) was measured using a high-speed screening impactor (FSI, Copley Scientific, UK). PSD: d = 15 μm and d = 55 μm; aPSD < 5 μm = 0%.

[0198] A typical method for PSD measurement was to disperse 80–100 mg of sample in 5 mL of silicone oil, mix thoroughly, and then sonicate for 20–30 s. Triplicate measurements were performed on the solution using a Malvern Mastersizer 2000 (Malvern Panalytical Ltd., UK).

[0199] General method for aPSD measurement: The filled device was run through a high-speed screening impactor (FSI, Copley Scientific, UK) equipped with the appropriate adapter, expansion valve, and 10-micron insert. The flow rate was adjusted to 30 ± 0.5 L / min. Results were reported as fine particle mass (FPM) as the % recovered in the filter stage (<5 μm).

[0200] Example 5 Naloxone-containing compositions A, C, and D Following the same general procedure as described in Example 4 above, three additional spray-dried powders were prepared having compositions according to Table 5 below. [Table 5]

[0201] Compositions A and C contained a single dose of 4 mg naloxone, and Composition D contained a single dose of 8 mg naloxone (each calculated as the HCl salt). The PSD and aPSD were analyzed using the general method described in Example 4 above (see Table 6 below for results). [Table 6]

[0202] Example 6 Intranasally administered naloxone - a pharmacokinetic study (healthy volunteers) A phase 1 clinical trial was conducted to determine the bioavailability of four investigational naloxone nasal powder formulations relative to the reference commercial product, NARCAN® Nasal Spray ("Reference"; naloxone hydrochloride liquid nasal spray, 4 mg; Adapt Pharma, Inc., Radnor, PA, USA).

[0203] This study was a single-center, open-label, randomized, single-dose, five-treatment crossover, comparative bioavailability study in healthy subjects. Subjects received each of the four naloxone-containing powders (Compositions A-D), as well as the reference, in order according to a pre-established randomization schedule, separated by a minimum 24-hour washout.

[0204] Subjects were randomized immediately before the first dose of investigational medicinal product (IMP) or reference (if used). A computer-generated randomization schedule was used to assign subject numbers to one of 10 treatment sequences (according to a balanced Williams design), with two subjects receiving each treatment sequence.

[0205] Forty-eight subjects were screened for inclusion in the study 28 days prior to dosing. Twenty-one eligible subjects (healthy men or women, non-pregnant, non-lactating, aged 18-55 years, with a body mass index of 18.0-32.0 kg / m) were recruited. 2 subjects) were admitted to the clinical unit the night before IMP administration (day −1) and remained on-site until discharge 24 hours after their final administration (after receiving all five treatments).

[0206] Subjects received IMP or reference on the mornings of days 1, 2, 3, 4, and 5, with appropriate intersubject intervals (approximately 10 minutes) based on logistical requirements. IMP was administered to alternate nostrils on each dosing day, starting with the left nostril on day 1. A follow-up phone call was conducted 3–5 days after the final dose to ensure the subject's continued health.

[0207] Of the 21 subjects enrolled, all received IMP. For analytical purposes, all 21 subjects were included in the safety population, safety analysis dataset, and PK population. One profile was excluded from the PK analysis dataset due to dosing failure, leaving 20 subjects who completed the study and were included in the PK analysis dataset. Plasma concentrations of naloxone were analyzed using non-compartmental analytical methods to obtain estimates of standard PK parameters, as follows: [Table 7]

[0208] Evaluation of safety parameters consisted of analysis of adverse events (AEs), intranasal tolerability, laboratory evaluations, vital signs, electrocardiogram (ECG), and physical examination findings.

[0209] Log-transformed exposure parameters (AUC and Cmax) were compared with standard methods to assess relative bioavailability using the SAS software procedure PROC MIXED. A single mixed-effects model was fitted to each parameter to obtain estimates of geometric mean ratios (GMRs) and corresponding confidence intervals (CIs) for all treatment comparisons of interest. The model included terms for actual treatment received, study day (i.e., period), and planned sequence fitted as fixed effects and subjects within sequence fitted as random effects. Results were back-transformed to a linear scale and displayed. The following comparisons were of interest: Relative bioavailability compared to the reference:IMP of AUC(0~t), AUC(0~infinity), and Cmax were determined. Early exposure compared to the reference:IMP of AUC(0-4 min), AUC(0-10 min) and AUC(0-30 min) was determined. Dose proportionality of the IMD formulation: AUC(0~t), AUC(0~infinity), and CMAX of 8mg:4mg GMR were determined and dose normalized.

[0210] result Arithmetic mean naloxone plasma concentrations (linear scale) versus time for each treatment are shown in Figures 10 and 11 (first 5 hours and first hour post-dose, respectively) and are listed below in Table 7. Geometric mean naloxone plasma concentrations (semi-log scale) versus time for each treatment are listed below in Table 7. [Table 8]

[0211] The analysis of relative bioavailability (GMR, CI 90%) is shown in Table 8 below. [Table 9]

[0212] All IMPs demonstrated significantly higher naloxone total and peak plasma exposures than the reference. Composition B demonstrated the highest relative bioavailability among the 4 mg formulations, with an average AUC approximately 84% higher and a CMAX 175% higher than the reference. (Note that formulation D contained 8 mg of naloxone hydrochloride, twice the amount of the other formulations.) IMPs A, B, C, and D also demonstrated lower interpatient variability (CV) than the reference for total and peak exposure parameters (see Table 7).

[0213] Tables 9 and 10 below show descriptive statistics (as geometric means, geometric CV%) of the partial AUC of naloxone by treatment on an absolute (Table 9) and relative (Table 10) basis. [Table 10] [Table 11]

[0214] All IMPs demonstrated significantly higher naloxone plasma exposures than the reference in the first 4, 10, and 30 minutes after administration. For Composition B, the early portion AUC GMR was much higher than the corresponding AUC(0~t) GMR for this IMP, indicating a higher initial absorption rate from this formulation than the reference.

[0215] Analysis of dose proportionality of IMP as dose-normalized GMR (CI 90%, 8 mg:4 mg, D:A) is shown in Table 11 below. [Table 12]

[0216] For the scaled point estimates of D:A GMR for AUC(0 to t), AUC(0 to infinity), and CMAX, 90% of the CIs are completely below 100%.

[0217] All IMPs demonstrated significantly higher naloxone exposure than the reference. Compositions A, B, C, and D demonstrated overall exposures that were approximately 36%, 84%, 37%, and 112%, respectively, higher than the reference, with peak exposures (CMAX) that were, on average, 50%, 175%, 58%, and 113%, respectively. (Again, note that Composition D contains 8 mg of naloxone hydrochloride, twice the amount of the other compositions.)

[0218] The inter-subject variability of the overall exposure parameters AUC(0 to t), AUC(0 to infinity), and CMAX was lower after administration of Compositions A, B, C, and D compared to the reference.

[0219] As can be seen clearly in Figure 10 and even more clearly in Figure 11, rapid absorption was observed for all formulations, with median Tmax values ​​ranging from 0.250 hours to 0.333 hours. Early exposure (in terms of AUC(0-4 minutes), AUC(0-10 minutes), and AUC(0-30 minutes)) was higher for all IMPs than the reference. Absorption was fastest for Composition B, with point estimates showing exposure over 270% higher than the reference in the first 10 minutes after administration. This is a remarkable and completely unexpected result for all the reasons previously mentioned.

[0220] Naloxone elimination was similar across all formulations, with arithmetic mean terminal T values ​​ranging from 1.243 to 1.471 hours.

[0221] Nasal administration of naloxone nasal powder at all doses was considered safe and well tolerated under the conditions of the study.

[0222] No serious adverse events (SAEs), severe adverse events (AEs), or adverse events leading to subject withdrawal were reported in this study, and the AE profile was similar to that of previous studies of the reference nasal spray in healthy subjects. The most commonly reported adverse events were nasal irritation, headache, and dizziness. All adverse events were mild in severity, and overall, the safety profile of IMP was consistent with previous experience with naloxone HCl in healthy subjects, with no findings raising safety concerns.

[0223] Example 7 Physical stability of spray-dried powders containing dextrins. Using the general procedure described in Example 1 above, two formulations were made with the following compositions (percentages are by weight of the total composition): Composition X Naloxone HCl (35%), 2-hydroxypropyl-β-cyclodextrin (Cavasol W7, HP Pharma, Wacker, Germany; 53%), lactose (Merck, Germany; 10%), and Tween 20 (Croda Nordica AB, Sweden; 1%) Composition Y Naloxone HCl (17%), maltodextrin (Glucidex IT 12 DE, Roquette, France; 72%), lactose (10%), sucrose monolaurate (1%).

[0224] An experiment similar to that described in Example 2 above was set up to measure the physical stability, as Tg values, of Compositions X and Y at different RH values. The results are shown in Table 12 below. [Table 13]

[0225] Both dextrins exhibited an increased Tg compared to compositions containing only lactose as the carrier material, facilitating acceptable released doses even after 24-72 hours of storage at 80° C. The multiple Tg values ​​shown in Table 10 indicate that the relevant compositions are not completely homogenous, but rather regions of increased concentration of high molecular weight polysaccharides separated from regions of lower molecular weight compounds.

[0226] Subsequent dissolution studies also showed that high concentrations of maltodextrin did not affect the dissolution of naloxone.

[0227] Example 8 Chemical stability of spray-dried powders containing dextrins. To investigate the chemical stability of naloxone as a function of dextrin and lactose / dextrin mixtures, samples were prepared using the general procedure described above in Example 1. The compositions (percentages are by weight of the total composition) are shown in Table 13.

[0228] The chemical stability of naloxone after 3 and 6 months at 40°C / 75% RH, where the amount of impurities is expressed as percentage of related substances (%RS), is summarized below in Table 13 for different formulations. All initial %RS values ​​were below 0.1%. [Table 14]

[0229] The numbers in parentheses in Table 13 are %RS excluding the values ​​measured for Impurity E (Imp E), a documented impurity related to naloxone (dimer). In this study, Imp E appears to be formed during sample preparation prior to analysis, which affects the total %RS value in an uncontrolled manner and prevents the detection of small degradation trends.

[0230] As can be seen from Table 13, dextrin unexpectedly induces degradation of naloxone, but the addition of lactose mitigates this effect.

[0231] Example 9 Nalmefene-containing compositions E, F and G Following essentially the same general procedures as described in Examples 1 and / or 4 above, three nalmefene-containing spray-dried powders were prepared with compositions according to Table 14 below. In this and the following examples, nalmefene was supplied by Mallinckrodt Inc., USA. [Table 15]

[0232] Compositions E and F contained a single dose of 3 mg nalmefene, and composition G contained a single dose of 3 mg nalmefene, but at half the strength and twice the fill weight (each calculated as the free base). The PSD and aPSD were analyzed using the general method described in Example 4 above (see Table 15 below for results). [Table 16]

[0233] Using the method described in Example 2 above, all compositions exhibited a glass transition at approximately 60° C. at ambient conditions. However, composition E experienced significant crystallization at temperatures slightly above 100° C., which was not observed in maltodextrin-containing compositions F and G. Additionally, composition E underwent crystallization at room temperature at 60% RH, which was not observed in compositions F and G.

[0234] Example 10 Chemical stability of spray-dried powders containing nalmefene Samples were prepared using the general procedures essentially as described above in Examples 1 and / or 4. The compositions (percentages are weight percent of the total composition) are shown in Table 16 below.

[0235] The chemical stability of nalmefene at 40°C / 75% RH for 3 and 6 months, where the amount of impurities is expressed as percentage of related substances (%RS), is summarized below in Table 16 for different compositions. All initial %RS values ​​were less than 0.1%. [Table 17] [Brief explanation of the drawings]

[0236] [Figure 1] FIG. 1 is a diagram illustrating the present invention. [Figure 2] FIG. 1 is a diagram illustrating the present invention. [Figure 3] FIG. 1 is a diagram illustrating the present invention. [Figure 4] FIG. 1 is a diagram illustrating the present invention. [Figure 5] FIG. 1 is a diagram illustrating the present invention. [Figure 6] FIG. 1 is a diagram illustrating the present invention. [Figure 7] FIG. 1 is a diagram illustrating the present invention. [Figure 8] FIG. 1 is a diagram illustrating the present invention. [Figure 9] FIG. 1 is a diagram illustrating the present invention. [Figure 10] FIG. 1 is a diagram illustrating the present invention. [Figure 11] FIG. 1 is a diagram illustrating the present invention.

Claims

1. A solid pharmaceutical composition in the form of a spray-dried powder suitable for nasal delivery of an opioid antagonist, comprising a pharmacologically effective amount of an opioid antagonist selected from naloxone, nalmefene, or naltrexone, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier material comprising a combination of low molecular weight disaccharides, including lactose and / or trehalose, and a dextrin, including a cyclodextrin or maltodextrin.

2. 10. The composition of claim 1, wherein the powder has a particle size distribution with a d10 greater than 3 μm±0.3 μm.

3. The composition described in claim 1 or 2, wherein the powder has a particle size distribution including a d90 that is less than 500 μm ± 50 μm.

4. The composition described in claim 1 or 2, wherein the powder has a particle size distribution including a d90 that is less than 100 μm ± 10 μm.

5. The composition of claim 1, wherein the powder has a particle size distribution comprising a volume-based mean diameter in the range of 10 μm±1 μm to 100 μm±10 μm.

6. A composition described in any one of claims 1 to 5, further comprising a sucrose ester.

7. The composition of claim 6 , wherein the sucrose ester comprises sucrose monolaurate.

8. A composition described in claim 6 or 7, wherein the sucrose ester is present in an amount of 0.1% by weight to 3% by weight based on the total weight of the composition.

9. A composition described in any one of claims 1 to 8, wherein the dextrin comprises maltodextrin.

10. The composition of any one of claims 1 to 9, wherein the dextrin comprises 2-hydroxypropyl-β-cyclodextrin and / or maltodextrin 12DE.

11. The composition of any one of claims 1 to 10, wherein the disaccharide is present in an amount of 10% to 30% by weight based on the total weight of the composition.

12. The composition of any one of claims 1 to 11, wherein the dextrin is present in an amount of 40% to 70% by weight based on the total weight of the composition.

13. 13. The composition of any one of claims 1 to 12, wherein the ratio of disaccharide:dextrin is from 10:1 to 1:10 by weight, based on the total weight of the composition.

14. 14. The composition of any one of claims 1 to 13, wherein the composition has a lowest measurable glass transition temperature of at least 40°C when measured at a maximum relative humidity of 35%.

15. The composition of any one of claims 1 to 14, wherein the composition is essentially free of water.

16. 16. The composition of any one of claims 1 to 15, comprising less than 5% water.

17. 17. The composition of any one of claims 1 to 16, comprising less than 2% water.

18. 18. The composition of any one of claims 1 to 17, comprising less than 1% water.

19. 19. The composition of any one of claims 1 to 18, wherein the opioid antagonist or pharmaceutically acceptable salt thereof is chemically degraded by less than 15% after 3 months at 75% relative humidity and 40°C.

20. The composition of any one of claims 1 to 19, wherein the opioid antagonist is naloxone or a pharmaceutical salt thereof.

21. The composition of any one of claims 1 to 19, wherein the opioid antagonist is nalmefene or a pharmaceutical salt thereof.

22. A process for producing a composition according to any one of claims 1 to 21, said process comprising the following steps: i) mixing the opioid antagonist or salt thereof and the pharmaceutically acceptable carrier material, and, if present, the sucrose ester together in a suitable volatile solvent; and ii) spray drying the mixture from step i) to form a plurality of spray-dried particles. The process includes:

23. A nasal applicator device suitable and / or adapted to deliver a composition according to any one of claims 1 to 21 to the nose, the nasal applicator device comprising a reservoir or associated and / or attached to a reservoir, the composition being contained within said reservoir.

24. 24. A process for manufacturing an applicator device as described in claim 23, comprising the process described in claim 22, followed by loading the composition thus formed into a reservoir within the applicator device or attached or mounted to the applicator device.

25. A nasal applicator device as described in claim 23, packaged in a container that substantially prevents the ingress of atmospheric water under storage conditions of 75% relative humidity and 40°C.

26. 26. The nasal applicator device of claim 25, wherein the container comprises a material selected from the group of a heat-sealed aluminum pouch and a thermoformed plastic.

27. 27. A process for manufacturing an applicator device as described in claim 25 or 26, comprising the process as described in claim 24, followed by loading the applicator device into a container that substantially prevents the ingress of atmospheric water.

Images